Table 2. A variety of studies have demonstrated that CAR-T cells are characteristic of leukemia .

Disease	Target antigen	CAR features	Percentage of total rate	conditions of research	Reference
DLBCL, MCL	CD19	CD8-alpha hinge and transmembrane domains	70%	clinical study	83
MCL, CLL	CD19 and CD20	Local is produced	< 60%	clinical study	84
B-cell ALL	CD19 and CD22	Bi-specific CAR; intracellular signaling domains 4-1BB and CD3ζ	< 80%	In vivo	85
DLBCL, MCL	CD19	Number of T cells enriched for central memory (A) and aimless memory (B)after CAR T injection on day 2	A = 100% B < 80%	clinical study	86
DLBCL, CLL	CD19	Express 4-1BBL	< 50%	clinical study	87
DLBCL,PMBCL, MCL, MALT	CD19alone(A) or CD19 plus another target(B)	Tumor biopsies stained for CD19, CD20, CD22, CD30, CD38, CD70, and PMSA. Choice of CAR T target based on staining results	Single A = 50% Double B > 90%	-	88
AML	CD123 and CD33	The presence of CD28OX40z increases the killing of CIK cells significantly	N/A	In vivo	89
AML	FRβ	Contains CD8a hinge domains and transmembrane domain with intracellular CD3z, alone or with CD28 signal range	N/A	In vivo In vitro	90
MM	BCMA	t has a CD137 (4-1BB) excitation motif and a CD3-zeta signal range	< 80%	clinical study	91

DLBCL: Diffuse large B-cell lymphoma; MCL: Mantle cell lymphoma; CLL: Chronic lymphocytic leukemia; B-cell ALL: B-cell acute lymphoblastic leukemia;

PMBCL: Primary mediastinal B-cell lymphoma; MALT: mucosa-associated lymphoid tissue; AML: Acute myeloid leukemia; MM: Multiple myeloma.